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ABSTRACT
Objective: To analyze and validate 6-mercaptopurine (6-MP) and 6-methylmercaptopurine (6-MMP) in dried blood spots (DBS) using liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Methods: Bio-sampling dried blood spot with DBS-CAMAG® paper diameter of 8 mm and extracted with acetonitrile-methanol (1:3) containing internal standard 5-fluorouracil (5-FU). Separation was performed with C18 column Acquity® 1.7 μm (2.1 mm × 100 mm), with a mobile phase mixture 
of 0.1% formic acid in water 0.1% formic acid in acetonitrile with gradient elution and flow rate 0.2 ml/min. Mass detection was Waters Xevo TQD 
with positive electrospray ionization (ESI) for 6-MP, 6-MMP and negative ESI for 5-FU in multiple reaction monitoring modes. The ions of 6-MP was 
detected at m/z 153.09->119.09, 6-MMP at m/z 167.17->126.03, and 5-FU at m/z 129.15->42.05.
Results: This method fulfill the requirements of selectivity, linearity, lower limit of quantification, accuracy, precision, carry-over, matrix effects, 
and stability which refers to the european medicines agency (EMEA) guidelines. The linearity of 0.99 was 26-1000 ng/mL for 6-MP and 6-MMP, 
respectively. The validated method was applied to two childhood ALL maintenance phase. Retrieved 6-MP levels of 10.37 pmol/8×108 erythrocytes, 
respectively. The levels of 6-MMP gained 16.59 pmol/8×108 erythrocytes, respectively.
Conclusion: The developed LC/MS-MS method is valid to analysis 6-MP and 6-MMP in DBS simultaneous in vitro according to EMEA guidelines. The method was successfully applied to authentic capillary blood samples from two childhood patients with ALL in the maintenance phase.
Keywords: 6-mercaptopurine, 6-methylmercaptopurine, Dried blood spots, Acute lymphoblastic leukemia.
INTRODUCTION6-mercaptopurine (6-MP) is an antineoplastic drug which belongs to antimetabolites drug and widely used in childhood acute lymphoblastic 
leukemia (ALL) medication in single or combination dose [1]. It is a prodrug with individual dose based on patient’s body surface 
are because of the reason, the administration of the drug should be monitored. The usual bio-sampling method for therapeutic drug 
monitoring is performed through a vein (venipuncture) [2]. This 
method has many disadvantages such as requires a large volume, 
inefficient in storage and distribution, need experts to obtain the blood, 
and painful to the patients [3,4]. Dried blood spot (DBS) sampling has many potential advantages such as minimum invasive because 
using a sterile lancet needle in the fingers, toes or heel, small sample 
volumes ranging from 10 to 80 µl, efficient storage and distribution, 
prolonged sample stability, lower risk of infections, and comfortable for 
the subject [5,6]. Because the sample is taken from a peripheral vein 
in small volume, causing the analyte and the hematocrit interfering 
with the quantitative analysis of the drug molecule. Therefore, it needs 
rapid, sensitive, and selective method for quantification with liquid chromatography-tandem mass spectrometry (LC-MS/MS) [7-9].Analysis of 6-MP and its metabolites in erythrocytes and plasma using high performance liquid chromatography (HPLC) and LC-MS/MS has 
been developed [1,10]. There is no report described the development of an analytical method to determine 6-MP in DBS. The novelty of the 
research is describes a simple, rapid, sensitive, and selective LC-MS/MS method for determining 6-MP and 6-methylmercaptopurine (6-MMP) 
in DBS and its application of this method in childhood ALL patients. 
This study performed assay validations, according to the european 
medicines agency (EMEA) guidelines [11].
METHODS
Chemicals and materials6-MP (C5H4N4S), 6-MMP (C6H6N4S), and 5-fluorouracil (5-FU) (C
4
H3N2O2F) were purchased from Sigma-Aldrich (St. Louis, MO, USA), 
acetonitrile and methanol of HPLC grade were purchased from Merck 
(USA), purified water was prepared by a Millipore Direct-QTM 5 water 
system (Millipore, Watford, UK), sampling paper DBS w
as purchased from CAMAG, and whole blood from a blood bank 
(Indonesian Red Cross, Indonesia).
Instrument and chromatographic conditionThe chromatography was performed on Waters Acquity® UPLC bridged ethylene hybrid C18 column 1.7 µm (2.1 mm × 100 mm). The flow rate 
was 0.2 ml/min using a gradient elution starting with 95% water 
with 0.1% formic acid and 5% acetonitrile with 0.1% formic acid. The mass selective detector operated in electrospray ionization positive 
mode for 6-MP and 6-MMP, a negative mode for internal standard (IS) 5-FU as internal standard (IS). Mass spectrometric detection 
was performed on Waters Xevo TQD Triple Quadrupole (Waters, 
Milford, USA); multiple reaction monitoring was employed with mass 
resolutions of wide for MS1 and widest for MS2. High purity nitrogen 
was used as source and collision gas. For data analysis, Waters Masslynx 
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software was used.
Standard solutions
All stock solutions were prepared using ammonium hydroxide at a 
concentration of 1.0 mg/ml and stored at −20°C, for calibration curve 
standard the stock solutions were diluted to yield 6-MP concentrations 
of 26-1000 ng/ml and 6-MMP concentrations of 13-500 ng/ml.
DBS sample preparation and extraction
An aliquot of 40 µl spiked blood was spotted on the sampling paper with a graded capillary tube and dried for a minimum of 3 h. Cut the spot with 8 mm diameter. After that transferred it into a 5 ml polypropylene 
tube, add 100 µl IS, then extract it with 3 ml methanol and 1 ml 
acetonitrile, vortex for about 30 s and sonicated for 25 min at 60°C 
temperature, then centrifuged (room temperature, 3100 ×g, 15 min). Supernatant transferred in the sample tube and evaporated under a 
gentle stream of nitrogen at 40°C temperature. After reconstituting the 
extract with 100 µl mobile phase, vortex for about 30 s and centrifuge 
(room temperature, 3100 ×g, 5 min), 10 µl of each sample was analyzed by LC-MS/MS.
Method validationAssay validation was performed according to the EMEA guidelines for 
validation of bioanalytical assays [11]. In addition, experiments were conducted to determine the effects of volume of blood used to prepare 
the DBS, the effects of different hematocrit values, and the effects of DBS 
on the selectivity, carry-over, lower limit of quantitation, calibration 
curve, accuracy, precision, dilution integrity, matrix effect, and stability of the method.
Application of the method to authentic samplesCapillary blood from two patients spotted on a sampling paper and 
dried for at least 3 h. After drying, then the spots were packed in a sealed plastic bag with desiccant and stored at room temperature until analysis as described above.The study protocol was approved by the Committee of the Medical 
Research Ethics of the “Dharmais” Cancer Hospital, with a KEPK/019/
IV/2016 reference number for notice of approval.
RESULTS
Blood sampling procedure
For a sampling of an actual blood volume, we screened from several 
volumes; then, the spiked blood was spotted on papers DBS is 20 µl, 
40 µl, and 80 µl. Accurate blood volume spotted on DBS card 40 µl.
Optimizing sample preparationExtraction process from DBS sample is optimized by following 
parameters composition and volume of extraction, solution temperature and time of sonication. The preparation method was chosen based on area IS an analyte. The first experiment was performed with acetonitrile 
1 ml, 1.5 ml, methanol 1 ml, 1.5 ml of methanol and a mixture of both as much as 1 ml. The recovery obtained from all the method above was 
unqualified. Therefore, for further optimization, we add variation in 
composition and volume of extraction solution, and the best recovery 
obtained in the mix methanol-acetonitrile (3:1) in increments of 4 ml (Fig. 1).
The recovery of 6-MP and 6-MMP was low on the organic solvent, due to different polarity between analyte and solvent. To overcome 
the shortcomings regarding solubility, we optimized the sonication temperature. Increasing the temperature of sonication is expected to increase the solubility of analyte in methanol and acetonitrile. 
Temperatures then optimized by 50°C, 60°C, and 65°C, respectively, 
for 30 min. The optimum temperature is 60°C (Table 1), increasing the temperature of sonication resulting a significant increase in area. It is 
believed that temperature is increasing the solubility of the analyte, so the amount that also extracted increases. After the temperature is 
optimized, we optimized the time of sonication in 15, 25, and 30 min, 
the optimum is 25 min. The increased time of sonication will lower 
6-MP area, but increasing 6-MMP area.
Validation assay
Selectivity and hematocrit
The selectivity of the method was determined with blank blood 
spots and spiked blood spots for lower limit of quantification (LLOQ) concentration from six different blood lots. The proportion of cells in 
a blood sample is termed hematocrit; there are no definitive levels for 
normal human hematocrit value, as the levels change with age, sex, and general health. The optimized methods were selective for 6-MP 
and 6-MMP in different hematocrit value (25%, 35%, 40%, 45%, and 
50%); no interfering signals were observed (Figs. 2 and 3). Selectivity 
was 9.93% coefficient of variation (CV) and −16.6-11.28% diff for 6-MP, 
12.85% CV and −17.71-15.37% diff for 6-MMP.
Carry-over
Carry-over should be assessed by injecting blank samples after a high concentration sample or calibration standard at the upper limit of 
quantification. Spiked quality control samples containing the analytes in concentrations representing the top range of the calibration standard were extracted and analyzed (n=5). Immediately after injection of the 
high concentration quality control sample, a blank matrix sample 
was injected. The analyte measured in the blank matrix samples was 
required to be ≤20% of the LLOQ, for the IS ≤5%. No carry-over was observed for any of the analytes including the IS (Table 2).
Fig. 2: Chromatograms showing the result of the extraction of 
blank
Fig. 3: Chromatograms showing the result of the extraction of 
lower limit of quantification
Fig. 1: Influence of the extraction acetonitrile (ACN) and methanol 
(Me-oh) on the analyte response peaks
122
Asian J Pharm Clin Res, Vol 10, Issue 9, 2017, 120-125
 Supandi et al. 
Calibration curve, linearity, and LLOQA calibration curve was prepared for 5 consecutive days. The 
relationship between the quotient peak area of the analyte/peak area of 
the IS and the concentration was linear for 6-MP, and 6-MMP within the range of the calibration curve. Linearity was evaluated by comparing the slopes of the calibration curves. The coefficients of correlation 
(6-MP ≥0.99 for 26-1000 ng/ml, 6-MMP ≥0.99 for 13-500 ng/ml) were 
determined. For determination of the LLOQ quality control samples 
with low concentrations were analyzed (n=5). The LLOQ, defined as the lowest concentrations that could be determined with a precision 
displaying a % CV and % diff of ≤20%. The LLOQ is 26 ng/ml for 6-MP and 13 ng/ml for 6-MMP. The purpose of the development of this 
method is the monitoring of drug therapy, where the levels of drug Cmax 
was taken at the time so that the LLOQ on this dry blood sample can be 
used for monitoring therapeutic drug 6MP for achievements LLOQ meet in the range of Cmax.
Accuracy and precision
Within-run and between-run precision and accuracy were calculated from data obtained during a 3 d validation period. Each the 3 d sample 
spiked with the chosen concentrations (each concentration n=5) 
were analyzed. Four selected concentrations covered a high, medium and low range and the lower limit of quantification of the calibration curve. Accuracy was evaluated by calculating the difference between 
measured values and nominal values (% diff); precision was calculated 
based on the % CV. Within-run accuracy and precision, respectively, 
were −12.76-11.90% diff and 3.79-6.95% CV for 6-MP. For 6-MMP 
−19.92-9.41% diff and 13.15-6.13% CV. The between-run accuracy and 
precision ranged between −15.40-17.96% diff and 3.09-9.22% CV for 
6-MP, −15.52-19.62% diff and 0.91-4.28% CV for 6-MMP. Therefore, all 
analytes were detected with sufficient accuracy and precision (±20% 
for LLOQ, ±15% for quality control low concentration [QCL], quality 
control medium concentration, and quality control high concentration 
[QCH]) (accuracy and precision data in Tables 3 and 4).
Matrix effectsMatrix effects were investigated for 6-MP and 6-MMP using 6 lots of individual human blood. The matrix factors (MF) were calculated for 6-MP and 6-MMP to obtain the IS normalized MF (MEIS). The response 
of post-spiked samples with known concentrations (QCL, and QCH) was compared with the response of non extracted solutions of the analyte at corresponding concentrations. The IS normalized MFs (MEIS) were 
found to be 8.40-10.06% CV for 6-MP and 7.66-8.07% CV for 6-MMP, and therefore the variability was within acceptable limits (Table 5).
Dilution integrationThis parameter aims to see that the dilution of samples in the analysis 
affect the accuracy and precision or not. Integrity dilution demonstrated 
by spiking the matrix with the analyte concentration above upper limit 
of quantification (ULOQ) and diluting this mixture with blank matrix (at least five determinations per dilution factor). Dilution integrity at half 
ULOQ was 11.37% CV and −6.68-13.55% diff for 6-MP, 6.58% CV and 
−13.36-4.30% diff for 6-MMP. At a concentration quarter, ULOQ was 
3.14% CV and 5.73-13.88% diff for 6-MP, 9.49% CV and −10.14-4.30% 
diff for 6-MMP. Therefore, all analytes were detected with sufficient 
accuracy (±15% relative error of the nominal value) and precision 
(within 15% relative standard deviation).
Stability
The stock solution stability was determined for one concentrations 
(1 mg/ml; each concentration n=5) under different conditions. Store 
the solution in room temperature for 24 h and at −20°C for 16 d. All solutions were stable under these conditions. The accuracy and 
precision was 0.21-0.60% CV and −0.34-0.43% diff for 6-MP, 0.04-
0.93% CV and −0.03-0.66% diff for 6-MMP, 0.09-2.54% CV and −0.06-
1.80% diff for 5-FU (Table 6).
To the determine the short-term stability, store the DBS in sealed 
plastic bags containing silica gel desiccants for 24 h, then determined by analyzing blood spots containing the analytes at two concentrations 
(QCL and QCH; each concentration n=3). The calculated concentrations, 
accuracy, and precision between samples immediately after drying for 3 hrs and the different time were determined and compared. The 
accuracy and precision was 2.64-8.20% CV and −8.61-12.24% diff for 
6-MP, 4.25-6.42% CV and −14.11-13.72% diff for 6-MMP (Table 7).
The stability of the extracted samples in the autosampler for 24 h was determined by analyzing blood spots containing the analytes at two 
concentrations (QCL and QCH; each concentration n=3). The calculated 
concentrations, accuracy, and precision between samples measure immediately after extraction and samples remaining in the autosampler 
for 24 h until measurement were calculated and compared. The 
accuracy and precision was 2.79-5.47% CV and −5.33-13.23% diff for 
6-MP, 1.60-4.90% CV, and −14.59-13.79% diff for 6-MMP. The result indicates that the compounds in the DBS and extracted samples were stable under the tested conditions (Table 8).
Analysis of authentic capillary blood samples from DBS
Subjects, were included, in this study are patients with ALL in children who are undergoing treatment in the maintenance phase. Retrieved two patients indicated its willingness to be a subject. Samples then carried out to the preparation and analyzed with methods that have been validated. The concentration of 6-MP found in  erythrocytes 
were 6.69 and 10.37 pmol/8 x 108 erythrocytes, for 6-MMP  were 6.02 
and 16.59 pmol/8 x 108 erythrocytes (with 3.91 x 108 and 4.33 x 108 
erythrocytes per 100 µl of packed erythrocytes in patient 1 and 2).
DISCUSSION
Accurate blood volume spotted on DBS cards 40 µl and it is spread 
evenly and absorbed rapidly. As for extraction method, we choose protein precipitation using methanol-acetonitrile (3:1) good recovery the analytes (Fig. 1). As shown in Table 1, its indicated sonication and evaporation step following the precipitation were added to concentrate its analyte they increase the response of analyte. Recovery of 6-MP 
and 6-MMP more than 90%, it concludes that the extraction method was successful producing high extraction yield. Validation assay was 
Table 1: Optimized temperature of sonication
Sonication temperature Area Time retention (min)
6-MP 6-MMP 5-FU 6-MP 6-MMP 5-FU
50°C 27,984±75.78 59,098±85.15 10,670±46.07 1.76±0.12 3.78±1.01 1.57±1.21
60°C 22,739±63.67 63,991±94.04 11,945±53.89 1.73±1.10 3.76±0.98 1.58±0.01
65°C 20,873±59.10 79,578±98.99 4853±47.78 1.73±1.11 3.76±1.21 1.57±1.11
Each value in the table was represented as mean±SD (n=3). SD: Standard deviation, 6-MP: 6-mercaptopurine, 6-MMP: 6-methylmercaptopurine, 5-FU: 5-fluorouracil
Table 2: Parameters of carry-over
Parameters Mean 
measured 
blank area
Mean 
measured 
LLOQ area
Mean 
measured 
carry-over (%)6-MP 100.80±50.61 713.51±46.74 14.05±6.696-MMP 70.20±27.44 1973.92±120.32 3.57±1.435-FU 78.8±68.01 7236.88±182.46 1.08±0.94Each value in the table was represented as mean±SD (n=5). SD: Standard 
deviation, 6-MP: 6-mercaptopurine, 6-MMP: 6-methylmercaptopurine, 
5-FU: 5-fluorouracil, LLOQ: Lower limit of quantification
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Table 3: Accuracy and precision of 6-MP
Analyte Actual concentration (ng/ml) Mean measured 
concentration (ng/ml)±SD (n=5)
Precision (% CV) Bias (% difference)
Within-run LLOQ (26) 25.56±1.74 6.82 (−10.17-8.36)
QCL (104) 103.59±3.82 3.69 (−4.36-4.28)
QCM (520) 539.73±21.07 3.90 (−0.11-8.99)
QCH (820) 877.70±44.07 5.03 (−0.67-14.07)Between-run LLOQ (26) 25.36±2.86 11.29 (−14.04-17.06)
QCL (104) 98.26±3.72 3.78 (−12.08-3.21)
QCM (520) 508.79±22.80 4.48 (−14.08-8.39)
QCH (820) 806.81±57.56 7.13 (−13.59-13.34)
LLOQ: Lower limit of quantification, QCL: Quality control low concentration, QCM: Quality control medium concentration, QCH: Quality control high concentration, 
6-MP: 6-mercaptopurine, SD: Standard deviation, CV: Coefficient of variation
Table 4: Accuracy and precision of 6-MMP
Analyte Actual concentration (ng/ml) Mean measured 
concentration (ng/ml)±SD (n=5)
Precision (% CV) Bias (% difference)
Within-run LLOQ (13) 10.96±0.71 6.44 (−19.84-7.04)
QCL (52) 51.42±5.69 11.07 (−7.21-8.58)
QCM (260) 261.44±19.18 7.34 (−10.59-8.19)
QCH (416) 401.95±24.84 6.18 (−9.71-5.91)Between-run LLOQ (13) 12.86±0.61 4.70 (−14.54-19.62)
QCL (52) 54.32±2.09 3.86 (−11.96-13.79)
QCM (260) 261.08±6.76 2.59 (−10.08-8.54)
QCH (416) 403.03±4.47 1.11 (−12.42-7.69)
LLOQ: Lower limit of quantification, QCL: Quality control low concentration, QCM: Quality control medium concentration, QCH: Quality control high concentration, 
SD: Standard deviation, CV: Coefficient of variation, 6-MMP: 6-methylmercaptopurine
Table 5: Matrix effects for 6-MP and 6-MMP
Blood lot Concentration (ng/ml) MF 6-MP (%) MF IS (%) MEIS (%) MF 6-MMP (%) MF IS (%) MEIS (%)1 QCL (104 for 6-MP, 52 for 6-MMP) 69.57 82.00 0.84 83.91 82.00 1.02
2 83.43 80.65 1.03 79.19 80.65 0.983 83.46 83.15 1.00 83.83 83.15 1.01
4 78.61 82.64 0.95 97.67 82.64 1.185 80.67 80.67 1.00 95.58 80.67 1.186 90.09 82.72 1.08 83.14 82.72 1.011 QCH (820 for 6-MP, 416 for 6-MMP) 76.66 82.00 0.93 91.31 82.00 1.11
2 70.64 80.65 0.87 80.39 80.65 0.993 66.94 83.15 0.80 88.51 83.15 1.06
4 63.58 82.64 0.76 80.58 82.64 0.975 67.13 80.67 0.83 73.46 80.67 0.916 85.24 82.72 1.03 85.18 82.72 1.03
MF: Matrix factors, MEIS: Internal standard normalized matrix factors, QCL: Quality control low concentration, QCH: Quality control high concentration, 
6-MMP: 6-methylmercaptopurine, 6-MP: 6-mercaptopurine
Table 6: Stock solution stability of 6-MP, 6-MMP, and 5-FU
Analyte Temperature Time Mean measured concentration 
(ng/ml)±SD (n=3)
Precision (% CV) Bias (% diff)
6-MP Room 0 hr 834.77 ± 58.60 0.60 (0.43-3.87)6 hrs 857.81 ± 88.81 0.27 (0.19-5.00)
24 hrs 987.54 ± 50.18 0.31 (0.22-3.76)
−20°C 8 days 984.77 ± 62.70 0.21 (0.15-4.77)16 days 998.81 ± 78.81 0.47 (−0.34-10.34)6-MMP Room 0 hr 878.54 ± 91.50 0.84 (0.59-9.23)6 hrs 875.64 ± 100.45 0.15 (−0.11-6.43)
24 hrs 885.70 ± 99.18 0.26 (−0.18-10.01)
−20°C 8 days 932.87 ± 101.72 0.04 (−0.03-5.99)16 days 977.41 ± 120.11 0.93 (0.66-6.43)5-FU Room 0 hr 911.24 ± 95.53 2.49 (1.76-2.98)6 hrs 953.62 ± 92.35 1.70 (−1.21-1.78)
24 hrs 979.17 ± 72.98 0.29 (0.21-5.21)
−20°C 8 days 1084.37 ± 102.72 0.09 (−0.06-3.22)16 days 1003.31 ± 120.16 2.54 (1.80-1.98)
Stock solution concentrations for 6-MP, 6-MMP and 5-FU 1000 ng/ml. 6-MMP: 6-methylmercaptopurine, 6-MP: 6-mercaptopurine, 5-FU: 5-fluorouracil, CV: Coefficient of variation
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performed and as reported above, in selectivity parameter found no interfering signals from different hematocrit value from the blood (Fig. 2). The result of carry-over was given in Table 2; no carry-over was observed for any of the analytes including the IS. Values of accuracy 
and precision within-run and between-run fulfill the range of ≤ ±15% 
for QC samples and ≤20% for LLOQ (Tables 3 and 4). As shown in Table 5, the MF value than less 100%, it concludes that indicated matrix compound causes ion suppression that can interfere with analyte 
ionization process, but % CV values were within limits requested by 
EMEA guidelines [2,11-14]. Analytes in stock solution stable at least 
for 16 days storage of −20°C. Analyte in DBS was stable for 6 days at 
room temperature and 24 hrs in the autosampler (stability data in Tables 6-8). The method has several advantages as compared to the 
literature [1,10] such as minimum volume sample, simple sample 
preparation procedures, short analysis time (5 min per sample), and high sensitivity which rendered for the purpose of its application. The result of application toward childhood ALL patients in maintenance 
phase showed the concentration of 6-MP and 6-MMP; the results indicated that the methods used are not disturbed by the metabolic processes in vivo (Fig. 4). Monitoring the levels of 6-MP and 6-MMP were necessary to get the right information related to the availability of the metabolite 6-MP both the active metabolite and inactive metabolites.
CONCLUSIONThe developed LC/MS-MS method is valid to analysis 6-MP and 6-MMP 
in DBS simultaneous in vitro according to EMEA guidelines. The method was successfully applied to authentic capillary blood samples from two patients with ALL maintenance phase.
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